Holen Sie sich die Stockscreener-App
698.99
0.61%
-4.2706
Schlusskurs vom Vortag:
$703.26
Offen:
$705.11
24-Stunden-Volumen:
370.51K
Relative Volume:
0.35
Marktkapitalisierung:
$73.48B
Einnahmen:
$14.25B
Nettoeinkommen (Verlust:
$4.58B
KGV:
16.73
EPS:
41.7701
Netto-Cashflow:
$3.88B
1W Leistung:
-5.80%
1M Leistung:
+6.30%
6M Leistung:
+35.04%
1J Leistung:
-11.30%
1-Tages-Spanne:
$696.00
$711.15
1-Wochen-Bereich:
$696.00
$744.23
52-Wochen-Spanne:
$476.49
$791.49
Regeneron Pharmaceuticals Inc Stock (REGN) Company Profile
Firmenname
Regeneron Pharmaceuticals Inc
Sektor
Branche
Telefon
(914) 847-7000
Adresse
777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY
Vergleichen Sie REGN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
REGN
Regeneron Pharmaceuticals Inc
|
699.12 | 73.91B | 14.25B | 4.58B | 3.88B | 41.77 |
|
VRTX
Vertex Pharmaceuticals Inc
|
440.01 | 112.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
416.75 | 56.81B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
892.74 | 55.46B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
193.50 | 41.92B | 447.02M | -1.18B | -906.14M | -6.1812 |
Regeneron Pharmaceuticals Inc Stock (REGN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-03 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-11-24 | Eingeleitet | HSBC Securities | Buy |
| 2025-11-24 | Fortgesetzt | Truist | Buy |
| 2025-11-13 | Eingeleitet | Scotiabank | Sector Perform |
| 2025-08-14 | Eingeleitet | Rothschild & Co Redburn | Buy |
| 2025-06-30 | Herabstufung | Argus | Buy → Hold |
| 2025-05-30 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-05-30 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2025-05-14 | Hochstufung | Citigroup | Neutral → Buy |
| 2025-04-22 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2025-02-05 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2025-01-16 | Herabstufung | UBS | Buy → Neutral |
| 2024-12-10 | Fortgesetzt | BofA Securities | Underperform |
| 2024-11-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-11-14 | Eingeleitet | Citigroup | Neutral |
| 2024-09-24 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2024-03-12 | Eingeleitet | Bernstein | Outperform |
| 2024-01-12 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Hold |
| 2023-11-03 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2023-08-21 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2023-08-21 | Bestätigt | Oppenheimer | Perform |
| 2023-06-28 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2023-03-27 | Hochstufung | SVB Securities | Market Perform → Outperform |
| 2023-03-24 | Hochstufung | Jefferies | Hold → Buy |
| 2023-03-23 | Hochstufung | Raymond James | Underperform → Mkt Perform |
| 2023-01-30 | Hochstufung | Cowen | Market Perform → Outperform |
| 2023-01-20 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-10-26 | Herabstufung | Raymond James | Mkt Perform → Underperform |
| 2022-10-17 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-09-09 | Hochstufung | Jefferies | Underperform → Hold |
| 2022-09-09 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2022-07-25 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2022-07-13 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2022-06-06 | Eingeleitet | Jefferies | Underperform |
| 2022-05-23 | Eingeleitet | SVB Leerink | Outperform |
| 2022-01-05 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2022-01-03 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2021-12-15 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Overweight |
| 2021-12-07 | Fortgesetzt | Cowen | Market Perform |
| 2021-12-06 | Eingeleitet | Goldman | Buy |
| 2021-11-19 | Fortgesetzt | BMO Capital Markets | Outperform |
| 2021-11-05 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2021-06-29 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-01-25 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2021-01-13 | Hochstufung | The Benchmark Company | Hold → Buy |
| 2021-01-08 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-10-05 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2020-08-20 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2020-07-09 | Hochstufung | SunTrust | Hold → Buy |
| 2020-05-26 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2020-04-28 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-04-17 | Hochstufung | The Benchmark Company | Hold → Buy |
| 2020-04-08 | Eingeleitet | The Benchmark Company | Hold |
| 2020-03-31 | Eingeleitet | Wolfe Research | Peer Perform |
| 2020-02-27 | Eingeleitet | Barclays | Overweight |
| 2020-02-26 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2020-02-26 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-02-25 | Hochstufung | Jefferies | Hold → Buy |
| 2020-02-11 | Hochstufung | Argus | Hold → Buy |
| 2019-12-24 | Eingeleitet | Raymond James | Mkt Perform |
| 2019-12-16 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2019-12-13 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2019-11-12 | Eingeleitet | SunTrust | Hold |
| 2019-11-07 | Hochstufung | Citigroup | Neutral → Buy |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Neutral |
| 2019-09-23 | Hochstufung | Guggenheim | Neutral → Buy |
Alle ansehen
Regeneron Pharmaceuticals Inc Aktie (REGN) Neueste Nachrichten
Regeneron Pharmaceuticals' Upcoming Melanoma Data Likely to Look Competitive, RBC Says - marketscreener.com
ASH takeaways: Regeneron unveils new data on blood cancer drugs, touts hematology pipeline - Medical Marketing and Media
Regeneron Pharmaceuticals Inc. stock underperforms Monday when compared to competitors - MSN
Here's Why You Should Retain OPKO Health Stock in Your Portfolio Now - TradingView
Ossiam Sells 22,234 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals Stock Slides 11% With A 8-Day Losing Spree - Trefis
Regeneron Pharmaceuticals: Is Wall Street Finally Paying Attention (NASDAQ:REGN) - Seeking Alpha
Regeneron’s (REGN) recovery and Dupixent strength support BMO’s outperform rating - MSN
Regeneron’s (REGN) Recovery and Dupixent Strength Support BMO’s Outperform Rating - Insider Monkey
Why Is Kymera Therapeutics Stock Skyrocketing Monday?Kymera Therapeutics (NASDAQ:KYMR) - Benzinga
Natixis Purchases 2,751 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Tessera Therapeutics Showcases New Preclinical Data Demonstrating Progress of In Vivo Programs for Sickle Cell Disease and T Cell Therapies at the 67th American Society of Hematology Annual Meeting - GlobeNewswire Inc.
Anti-VEGF Market Growth Outlook: USD 41.3 Billion by 2035 With - openPR.com
California Public Employees Retirement System Sells 158,734 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
14 Best US Stocks to Buy for Long Term - Insider Monkey
Regeneron (REGN) Showcases Promising Trial Data for Lynozyfic in Multiple Myeloma - GuruFocus
Regeneron Reports Promising Results from LINKER-MM4 Trial of Lynozyfic™ for Newly Diagnosed Multiple Myeloma - Quiver Quantitative
Lynozyfic™ (linvoseltamab) Monotherapy in Newly Diagnosed Multiple Myeloma (NDMM) Shows Impressive Responses, Supporting Rationale as a Potential Foundation in Frontline Treatment - The Manila Times
Federated Hermes Inc. Acquires 204,045 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Understanding Momentum Shifts in (REGN) - news.stocktradersdaily.com
Can Regeneron Pharmaceuticals Stock Recover If Markets Fall? - Trefis
Does Regeneron’s Choppy 2025 Share Price Reflect Its Long Term Growth Potential? - Yahoo Finance
Regeneron's experimental therapy combo effective in untreated cancer patients - Reuters
Marshall Wace LLP Has $125.95 Million Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Panagora Asset Management Inc. - MarketBeat
First Trust Advisors LP Increases Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Baird Financial Group Inc. Grows Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Amundi - MarketBeat
Canaccord Genuity Group Forecasts Strong Price Appreciation for Regeneron Pharmaceuticals (NASDAQ:REGN) Stock - MarketBeat
Is Regeneron Still Attractive After Recent Pipeline Milestones and Valuation Upside Signals? - simplywall.st
BMO Capital Markets Issues Positive Forecast for Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Price - MarketBeat
Can Regeneron Pharmaceuticals Inc. stock maintain growth trajectoryJuly 2025 Retail & Free Safe Entry Trade Signal Reports - Newser
Regeneron Pharmaceuticals, Inc. $REGN Shares Bought by Guggenheim Capital LLC - MarketBeat
Invesco Ltd. Grows Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Why Regeneron Pharmaceuticals Inc. (RGO) stock is listed among top recommendationsOptions Play & Community Driven Trade Alerts - Newser
Dodge & Cox Acquires 1,502,198 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals, Inc. $REGN Holdings Lowered by Epoch Investment Partners Inc. - MarketBeat
Will Regeneron Pharmaceuticals Inc. (RGO) stock profit from fiscal stimulus2025 Retail Activity & Daily Momentum Trading Reports - Newser
How Regeneron Pharmaceuticals Inc. (RGO) stock responds to job market shiftsJuly 2025 Trends & Weekly Setup with ROI Potential - Newser
Can Regeneron Pharmaceuticals Inc. (RGO) stock sustain institutional flowsJuly 2025 Update & High Accuracy Trade Alerts - Newser
Regeneron Pharmaceuticals, Inc. (REGN): A Bull Case Theory - Insider Monkey
Citi Healthcare In Brief: Launch Trajectories Under Scrutiny - Citeline News & Insights
Can Regeneron Pharmaceuticals Inc. stock sustain institutional interestMarket Volume Report & Weekly Top Stock Performers List - Newser
Market Whales and Their Recent Bets on REGN Options - Benzinga
REGN: BMO Capital Raises Price Target and Maintains Outperform R - GuruFocus
BMO Capital raises Regeneron Pharma stock price target to $850 on Dupixent growth - Investing.com
Regeneron Pharmaceuticals (NASDAQ:REGN) Rating Lowered to "Equal Weight" at Morgan Stanley - MarketBeat
Regeneron Pharmaceuticals, Inc. $REGN Stock Holdings Lifted by Lido Advisors LLC - MarketBeat
How Does Regeneron Pharmaceuticals Stock Stack Up Against Its Peers? - Trefis
Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Schroder Investment Management Group - MarketBeat
Canaccord Genuity Adjusts PT on Regeneron Pharmaceuticals to $1,057 From $850, Maintains Buy Rating - marketscreener.com
Finanzdaten der Regeneron Pharmaceuticals Inc-Aktie (REGN)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.23%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):